Evidence map›Paper›PMID 35518208›Full record

ArticleFrontiers in neurology2022

Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry.

Martin Vališ, Zbyšek Pavelek, Michal Novotný, Blanka Klímová, Jana Šarláková, Simona Halúsková, Marek Peterka, Ivana Štětkárová, Pavel Štourač, Jan Mareš and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Martin VališDepartment of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Zbyšek PavelekDepartment of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Michal NovotnýDepartment of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Blanka KlímováDepartment of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Jana ŠarlákováDepartment of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Simona HalúskováDepartment of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Marek PeterkaDepartment of Neurology, Faculty of Medicine, University Hospital Plzen, Charles University, Plzen, Czechia.
Ivana ŠtětkárováThird Faculty of Medicine, Charles University and Hospital Kralovské Vinohrady, Charles University, Prague, Czechia.
Pavel ŠtouračDepartment of Neurology, University Hospital, Masaryk University, Brno, Czechia.
Jan MarešDepartment of Neurology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czechia.
Pavel HradílekClinic of Neurology, University Hospital Ostrava, Ostrava, Czechia.
Radek AmpapaDepartment of Neurology, Hospital of Jihlava, Jihlava, Czechia.
Marta VachováDepartment of Neurology, KZ a.s., Hospital Teplice, Teplice, Czechia.
Eva RecmanováDepartment of Neurology, Tomas Bata Regional Hospital, Zlín, Czechia.
Eva MeluzínováDepartment of Neurology, Second Faculty of Medicine, Charles University, Prague, Czechia.
University Hospital Hradec Králové · CZCharles University · CZHospital Jihlava · CZMasaryk University · CZPalacký University Olomouc · CZRegional Museum in Teplice · CZUniversity Hospital Ostrava · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Multiple sclerosis can also affect children. Approximately 3-10% of patients develop multiple sclerosis before the age of 16. Objective: The aim of this analysis is to describe the characteristics of pediatric patients with multiple sclerosis who started their treatment with disease-modifying drugs in 2013-2020, with data obtained from the Czech National Registry of patients with multiple sclerosis. Design and Setting: A method of retrospective analysis conducted with 134 pediatric patients with multiple sclerosis was used. Results: The findings reveal that the mean age at the date of the introduction of the first disease-modifying drugs treatment is 15.89 years, and gender does not play any role. In addition, moderate (51.6%) and mild (45.2%) relapses are predominant in these young patients. Seventy five percent of patients will not experience a confirmed progression of the expanded disability status scale within 54.7 months from starting the treatment. Furthermore, the results confirm that the first-choice treatment is interferon beta-a and glatiramer acetate, which is common for adult patients. However, some factors, such as a low efficacy or a lack of tolerance may impact on treatment discontinuation in children. Conclusion: More research should be performed on novel disease-modifying drugs for this target group.

Indexed as

disease-modifying drugsglatiramer acetateinterferon beta-apediatric multiple sclerosisrelapsing-remitting form

Identifiers

PMID35518208
PMCPMC9062179
OpenAlexW4224248158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.